Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 3, 2011, Pages 344-352

  Liang, Y ^a   Jiang, J ^a   Su, M ^a   Liu, Z ^a   Guo, W ^a   Huang, X ^a   Xie, R ^a   Ge, S ^a   Hu, J ^a   Jiang, Z ^a   Zhu, M ^a   Wong, V W S ^b   Chan, H L Y ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RELAPSE; TREATMENT RESPONSE; VIROLOGY;

EID: 79960013101     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04738.x     Document Type: Article

References (46)

1. Chan HL, Sung JJ,. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153-61. (Pubitemid 43668257)
2. Chan HL, Jia J,. Chronic hepatitis B in Asia-new insight from the past decade. J Gastroenterol Hepatol 2011; 26 (Suppl. 1): 131-7.
3. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26: 177-82.
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
5. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-5.
6. Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.
7. Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL,. Meta-Analysis: reduction of hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1059-68.
8. Wong VW, Wong GL, Chim AM, et al. Surrogate endpoints and long-term outcome in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2009; 7: 1113-20.
9. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 2169-79.
10. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alfa-2b. Gastroenterology 2008; 135: 459-67.
11. Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen positive chronic hepatitis B. Hepatology 2010; 51: 1945-53.
12. Liaw YF, Leung NW, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
13. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
14. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-39. (Pubitemid 46374607)
15. Ahn SH, Chan HL, Chen PJ, et al. Chronic hepatitis B: whom to treat and for how long? Proposition, challenges, and future directions. Hepatol Int 2010; 4: 386-95.
16. van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-4. (Pubitemid 36250065)
17. Lim SG, Amarapurkar D, Chan HL, et al. Reimbursement policies in Asia-Pacific for chronic hepatitis B. Hepatol Int 2010; 4: 20.
18. Chan HL,. Antiviral therapy for chronic hepatitis B: the challenges of Hong Kong. J Hepatol 2009; 51: 1088-90.
19. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51. (Pubitemid 44958517)
21. Sung JJ, Amarapurkar D, Chan HL, et al. Treatment of chronic hepatitis B in Asia-Pacific countries: is the Asia-Pacific consensus statement being followed? Antivir Ther 2010; 15: 607-16.
22. Yeh CT, Hsu CW, Chen YC, Liaw YF,. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol 2009; 45: 114-8.
23. Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. Continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009; 104: 1940-6.
24. Hadziyannis SJ, Sevastianos V, Rapti IN, et al. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006; 1: 231A.
25. Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010; 51: 415-21.
26. Reijnders JGP, Perquin MJ, Zhang N, Hansen BE, Janssen HLA,. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-8.
27. Chan HL, Wang H, Niu J, Chim AM, Sung JJ,. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12: 345-53. (Pubitemid 46787979)
28. Liu F, Wang L, Li XY, et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011; 26: 456-60.
29. Chein RN, Yeh CT, Tsai SL, Chu CM, Liaw YF,. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-73.
30. Byun KS, Kwon OS, Kim JH, et al. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol 2005; 20: 1838-42. (Pubitemid 43961038)
31. Ryu SH, Chung YH, Choi MH, et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003; 39: 614-9. (Pubitemid 37204663)
32. Chan HL, Wong VW, Tse CH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007; 25: 891-8. (Pubitemid 46525336)
33. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M,. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51. (Pubitemid 350047463)
34. Lee JM, Park JY, Kim DY, et al. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010; 15: 235-41.
35. Manolakopoulos S, Bethanis S, Koutsonunas S, et al. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008; 27: 266-73.
36. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8. (Pubitemid 38736340)
37. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-8. (Pubitemid 350181604)
38. Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B. Hepatology 2010; 52: 1232-41.
39. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-90.
40. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ,. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-31.
41. Rijckborst V, Sonneveld MJ, Janssen HL,. Review article: chronic hepatitis B-antiviral or immunodulatory therapy? Aliment Pharmacol Ther 2011; 33: 501-13.
42. Wurthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-20.
43. Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48: 22-6.
44. Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW,. Serum HBsAg quantification can predict sustained response to lamivudine in patients with negative HBeAg: a long-term post-treatment study. Antivir Ther (in press).
45. Chan HL,. The significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. J Gastroenterol Hepatol 2011; 26: 8-12.
46. Wong VW, Chan HL,. Severe acute exacerbation of chronic hepatitis B-a unique presentation of a common disease. J Gastroenterol Hepatol 2009; 24: 1179-86.